Developing Groundbreaking Therapies that will Transform the Lives of Patients
DRIVEN BY:
- A Patient-Centric and Precision Medicine Approach
- Innovative and Highly Efficient Clinical Trial Design
- A Passionate Focus on Unmet Medical Needs
OUR PRIMARY FOCUS
PULMONARY HYPERTENSION
WHO Group 1
Pulmonary Hypertension
- Orphan Disease
- 50% Five Year Survival
- No Disease Modifying Treatments
WHO Group 2
Pulmonary Hypertension
- Most Common Form of Pulmonary Hypertension
- 50% Five Year Survival
- No Effective Treatments At All
